Last reviewed · How we verify
antipsychotic medications
At a glance
| Generic name | antipsychotic medications |
|---|---|
| Sponsor | Janssen-Cilag, S.A. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Incentives and Long-Acting Injectable Adherence After Involuntary Hospitalization (NA)
- Cue-based Intervention in Prospective Memory and Medication Adherence. (NA)
- Psychiatric Multi-omics and Neuroimaging Project
- Cognitive Impairment Characteristics and Biological Mechanisms in Untreated Severe Mental Illness
- Medication Adherence in Severe Mental Illness: a Promotion Program (NA)
- Pharmacist-led Interventions in Psychiatric Patients (NA)
- Predictive Validity of the Personal and Social Performance Scale for PANSS Outcomes in Schizophrenia (PHASE2)
- An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- antipsychotic medications CI brief — competitive landscape report
- antipsychotic medications updates RSS · CI watch RSS
- Janssen-Cilag, S.A. portfolio CI